Biocytogen

✨ Biocytogen at AACR 2025 Booth #4008 ! 🐭 We’re excited to be exhibiting at AACR 2025 from April 25th–30th in Chicago! This premier event brings together the brightest minds in oncology, and we can’t wait to connect, collaborate, and explore the latest breakthroughs shaping the future of cancer research. At Biocytogen, we’re committed to advancing therapeutic antibody assets and preclinical solutions to accelerate drug discovery. AACR is the perfect opportunity to engage with industry experts, discuss emerging technologies, and drive innovation forward. Let’s connect in Chicago and make an impact together! 🔬✨ Read More: https://lnkd.in/et_Fx9hw #AACR2025 #CancerTherapeutics #Oncology #Biocytogen #MolecularTargets #DrugDiscovery #BiotechInnovation

🎉 Keynote Speaker Spotlight: SAPA-NE 2025 Antibody Workshop 🎉 We're thrilled to spotlight Dr. Qiurong Wang, Business Development Director at Biocytogen! 🔬 Speech Topic: "Accelerating Bi- & Multi-Specific and ADC Drug Discovery with Drug-Targeted Humanized Mouse Models" Dr. Wang will share her expertise in leveraging advanced humanized mouse models to fast-track the development of innovative bi-specific, multi-specific, and Antibody Drug Conjugate (ADC) therapies. 📅 When: Saturday, March 29, 2025 | 1:00 PM – 5:00 PM EDT 📍 Where: Lilly Seaport Innovation Center, Boston, MA 👉 Reserve your spot now: https://lnkd.in/eTpUXDck Special thanks to our event sponsors: GenScript and Kactus Join us to gain insights, connect with leaders, and shape the future of therapeutic innovation! 🚀 #SAPA_NE #SAPANE #BiotechInnovation #ADC #HumanizedModels #DrugDiscovery #KeynoteSpeaker #Networking #GenScript #Kactus

🐭 Meet Me at AACR 2025 Booth#4008! 🔬 Hi everyone, I’m Bickey, the Director of Luck at Biocytogen! I'll be at the AACR Annual Meeting 2025 in Chicago, April 25-30. At Biocytogen, we’re advancing oncology research with innovative therapeutic antibody assets and preclinical solutions. Let’s connect and discuss how innovation is shaping the future of cancer treatment. See you in Chicago! 💙 #AACR2025 #CancerResearch #Oncology #Biocytogen #DrugDiscovery #InnovationsInBiotech

Driving the Future of Antibody Therapeutics with RenMice® 🚀 Antibody therapeutics are transforming modern medicine, offering targeted solutions for cancer, autoimmune diseases, and more. At Biocytogen, we’re leading the way in innovative antibody drug development with our RenMice® platform—powered by proprietary SUPCE technology. Our platform delivers a comprehensive solution for discovering fully human monoclonal antibodies, bispecific/multispecific antibodies, bispecific ADCs, VHH antibodies, and TCR and TCR-mimic antibodies. Since the launch of our RenMice series in 2019, we’ve established over 150 therapeutic antibody and multiple clinical asset agreements, alongside nearly 50 target-nominated licensing projects globally, including partnerships with leading multinational pharma companies. The RenMice® platforms we offer—RenMab™, RenLite®, RenNano®, RenTCR™, and RenTCR-mimic™—eliminate in vitro humanization, reduce development time, and improve clinical success. We are dedicated to pioneering first-in-class and best-in-class antibody therapies. Contact us today to discuss potential partnerships!💡✨ #AntibodyTherapeutics #Biocytogen #RenMice #BiopharmaInnovation #Oncology #Immunotherapy #DrugDiscovery #TCRTherapies #ADC #Biotech #ADC #VHH #TCRMimic #BispecificAntibodies #BispecificADC

🚀 Advancing Oncology Research with Cutting-Edge Models 🔬 Oncology research is evolving rapidly, paving the way for next-generation therapies with enhanced tumor selectivity and reduced systemic toxicity. Innovations like antibody-drug conjugates (ADCs), bispecific antibodies, and novel tumor vaccines are transforming the treatment landscape, bringing new hope to patients worldwide. 💡🎯 At Biocytogen, we advance oncology drug discovery with cutting-edge in vivo, in vitro, and ex vivo platforms, ensuring comprehensive and reliable drug validation. With proprietary gene-editing technology and advanced pharmacological expertise, we offer 850+ validated oncology-related humanized mouse models. From target identification to IND application, our models accelerate the development of safer, more effective cancer therapies. Together, let’s push the boundaries of innovation and transform the future of oncology! 🌍💙 Download our latest oncology brochure to learn more: https://lnkd.in/eUMG8HnS #OncologyResearch #CancerTherapeutics #Biocytogen #ADCs #BispecificAntibodies #TumorVaccines #DrugDiscovery #PrecisionMedicine

[NEWS] Biocytogen Expands to San Diego! 🌎 Biocytogen is thrilled to announce the opening of our new office in San Diego, California! This strategic expansion reinforces our mission to be the "global headstream of new drugs," accelerating antibody-based drug discovery and preclinical solutions. By integrating cutting-edge technologies and fostering new collaborations, we are dedicated to driving innovation in therapeutic antibody development and supporting the next generation of transformative medicines. With this new office, we continue to strengthen our global impact by: ✅ Strengthening Global Partnerships – Expanding collaborations with Top 20 pharma companies and biotech innovators to advance drug discovery. ✅ Enhancing Antibody Discovery – Empowering partners with our RenMice® fully human antibody platforms to accelerate therapeutic breakthroughs. ✅ Advancing Preclinical Solutions – Utilizing humanized models and robust preclinical solutions to reduce risks and optimize drug development. We’re excited to deepen our collaborations and drive innovation from San Diego to the world! 🌍 Let’s shape the future of drug discovery together! San Diego Site: 9920 Pacific Heights Blvd Suite 150, San Diego, CA 92121 Read More: https://lnkd.in/eQG_yuZH #Biocytogen #SanDiego #Biotech #AntibodyDiscovery #PreclinicalResearch #RenMice #Innovation #DrugDevelopment

🐭 The Power of Mice in Research 🐭 Mice share over 95% of their genes with humans, making them essential in advancing biomedical research and drug discovery. They’re used in various fields, from cancer research to gene-editing breakthroughs, and continue to play a crucial role in developing new therapies. Vote below and let us know what you think! 👇 #Biotech #MiceInResearch #CancerResearch #Immunotherapy #GeneEditing #DrugDiscovery #MedicalInnovation

🍀 Happy St. Patrick’s Day from Biocytogen! 🍀 We’re feeling extra lucky to be part of such an incredible biotech community! Just like the perfect four-leaf clover, groundbreaking drug discovery takes the right mix of science, strategy, collaboration—and maybe just a little bit of biotech magic. ✨🔬 A huge shoutout to Lincoln Property Company for hosting us—we had a fantastic time connecting, collaborating, and celebrating innovation! At Biocytogen, we’re on a mission to turn cutting-edge science into life-changing treatments, using our therapeutic antibody assets and preclinical solutions to speed up drug discovery. Because even in science, a little luck can go a long way—while cutting-edge innovation makes the real magic happen! 😉 Wishing everyone a day filled with luck, laughter, and biotech breakthroughs! 💚☘️ #HappyStPatricksDay #Biocytogen #LuckMeetsScience #BiotechBreakthroughs #ThankYouLincolnProperty

🔬 Advancing Immuno-Oncology Therapies with Biocytogen’s Target Humanized Mice 🚀 Immuno-oncology (IO) is transforming cancer treatment by harnessing the immune system to fight tumors. From immune checkpoint inhibitors that “release the brakes” on T cells, to ADCs delivering drugs directly to cancer cells, T cell engagers (TCEs) guiding immune cells to tumors, and CAR-T therapies reprogramming T cells to attack cancer, IO is advancing safer, more precise treatments. Biocytogen’s drug-targeted humanized mice accelerate IO drug discovery by enabling in vivo evaluations of drug efficacy, toxicity, and PK/PD in a human-relevant context. These models incorporate single or multiple human targets, such as immune checkpoints, tumor microenvironment molecules, and combinations like CD3E/CD3EDG on T cells with tumor-associated antigens (TAAs) for TCE evaluations. We also assess CAR-T cell efficacy across various tumor models, including in immunodeficient B-NDG mice, driving the discovery of innovative therapies.🔥💡 Discover how our models can fast-track your therapies—connect with us today! #Biocytogen #DrugDiscovery #OncologyInnovation #ImmunoOncology #CancerTreatment #ImmuneCheckpoint #ADC #TCellEngager #CART #HumanizedMice